Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

被引：0
|
作者：
Qi, Hui
Wang, Fuyang
Han, Bingrui
Wang, Xiaomin
Qiang, Xiangnan
Zhang, Zhixiang
Gu, Qiangyang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4673
引用
收藏
页数：2
相关论文
共 50 条
  • [1] An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
    Walji, Moneeza
    Assouline, Sarit
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 933 - 942
  • [2] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, M.
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan M.
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04): : 351 - 363
  • [3] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [4] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [5] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [6] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [7] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Hajime Yasuda
    Naoko Kaga
    Hikari Taka
    Tomonori Ochiai
    Tomohito Yamana
    Yoshiki Miura
    Midori Ishii
    Makoto Sasaki
    Jun Ando
    Miki Ando
    Cancer Chemotherapy and Pharmacology, 2024, 93 (3) : 265 - 268
  • [8] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Shingleton, Jennifer R.
    Dave, Sandeep S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +
  • [9] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Yasuda, Hajime
    Kaga, Naoko
    Taka, Hikari
    Ochiai, Tomonori
    Yamana, Tomohito
    Miura, Yoshiki
    Ishii, Midori
    Sasaki, Makoto
    Ando, Jun
    Ando, Miki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 265 - 268
  • [10] Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
    Corcoran, Sean R.
    Phelan, James D.
    Choi, Jaewoo
    Shevchenko, Galina
    Fenner, Rachel E.
    Yu, Xin
    Scheich, Sebastian
    Hsiao, Tony
    Morris, Vivian M.
    Papachristou, Evangelia K.
    Kishore, Kamal
    D'Santos, Clive S.
    Ji, Yanlong
    Pittaluga, Stefania
    Wright, George W.
    Urlaub, Henning
    Pan, Kuan-Ting
    Oellerich, Thomas
    Muppidi, Jagan
    Hodson, Daniel J.
    Staudt, Louis M.
    CANCER DISCOVERY, 2024, 14 (09) : 1653 - 1674
12345